A Budget Impact Analysis of Switching From Von Willebrand Factor/Factor VIII Plasma-Derived Concentrate With 2.4-1 Ratio to the Concentrate With 1-1 Ratio for the Management of Von Willebrand Disease in Qatar
Author(s)
Laila Shafei, BSc, MSc1, Rawan Al Froukh, BSc, MSc2, Amir M. Nounou, 1, BSc Pharm3, Emad A. Beshay, BSC4, Anas Hamad, MSc, PhD5.
1Pharmacist, National Center for Cancer Care and Research, Doha, Qatar, 2Doha Drug Store, Doha, Qatar, 3Pharmacy, NCCCR, Dubai, United Arab Emirates, 4Pharmacy, Doha Drug Store, Doha, Qatar, 5Hamad Medical Corporation, London, United Kingdom.
1Pharmacist, National Center for Cancer Care and Research, Doha, Qatar, 2Doha Drug Store, Doha, Qatar, 3Pharmacy, NCCCR, Dubai, United Arab Emirates, 4Pharmacy, Doha Drug Store, Doha, Qatar, 5Hamad Medical Corporation, London, United Kingdom.
OBJECTIVES: To assess the financial impact of introducing a plasma-derived (pd) von Willebrand Factor (VWF)/ Factor VIII (FVIII) concentrate with a 1-1 activity ratio (Wilate®), for von Willebrand Disease management (vWD) in Qatar. The pdVWF/FVIII concentrate currently used at the National Center for Cancer Care and Research (NCCCR) contains VWF and FVIII in 2.4-1 ratio.
METHODS: A model was developed from the Qatari public healthcare system perspective. The model incorporated direct medical costs, including drug acquisition, outpatient consultations, hospitalizations, laboratory testing, adverse event treatment, and complication management. With a five-year time horizon, the uptake of pdVWF/FVIII concentrate with 1-1 activity ratio is projected to increase from 20% in year one to 100% by year five. To evaluate variables’ impact on the results, sensitivity analysis was conducted.
RESULTS: Over the 5-year time horizon, the adoption of the pdVWF/FVIII concentrate with 1-1 ratio is expected to yield total cost savings of 5,287,434 Qatari Riyal (QAR). The average per-patient cost decreased by approximately 50% (324,201 QAR in the current scenario versus 162,310 QAR in the new scenario). Yearly savings increased from 331,526 QAR in year one to 1,816,661 QAR in year five. Cost savings were secondary to decrease in hospital admissions, and bleeding associated complications. In addition to, reduced number of consumed doses with Wilate and offered improved convenience for patients. The sensitivity analysis results showed that bleeding episode frequency and vWD prevalence have a major impact on the results.
CONCLUSIONS: In Qatar, using pdVWF/FVIII concentrate with a 1-1 ratio for the management of vWD would lead to significant cost savings over the five-year time horizon. These findings and existing clinical evidence support the introduction of the new pdVWF/FVIII concentrate with 1-1 ratio into treatment protocols.
METHODS: A model was developed from the Qatari public healthcare system perspective. The model incorporated direct medical costs, including drug acquisition, outpatient consultations, hospitalizations, laboratory testing, adverse event treatment, and complication management. With a five-year time horizon, the uptake of pdVWF/FVIII concentrate with 1-1 activity ratio is projected to increase from 20% in year one to 100% by year five. To evaluate variables’ impact on the results, sensitivity analysis was conducted.
RESULTS: Over the 5-year time horizon, the adoption of the pdVWF/FVIII concentrate with 1-1 ratio is expected to yield total cost savings of 5,287,434 Qatari Riyal (QAR). The average per-patient cost decreased by approximately 50% (324,201 QAR in the current scenario versus 162,310 QAR in the new scenario). Yearly savings increased from 331,526 QAR in year one to 1,816,661 QAR in year five. Cost savings were secondary to decrease in hospital admissions, and bleeding associated complications. In addition to, reduced number of consumed doses with Wilate and offered improved convenience for patients. The sensitivity analysis results showed that bleeding episode frequency and vWD prevalence have a major impact on the results.
CONCLUSIONS: In Qatar, using pdVWF/FVIII concentrate with a 1-1 ratio for the management of vWD would lead to significant cost savings over the five-year time horizon. These findings and existing clinical evidence support the introduction of the new pdVWF/FVIII concentrate with 1-1 ratio into treatment protocols.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE3
Topic
Clinical Outcomes, Economic Evaluation, Health Technology Assessment
Topic Subcategory
Budget Impact Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)